Cargando…
Repurposing of approved cardiovascular drugs
Research and development of new drugs requires both long time and high costs, whereas safety and tolerability profiles make the success rate of approval very low. Drug repurposing, applying known drugs and compounds to new indications, has been noted recently as a cost-effective and time-unconsuming...
Autores principales: | Ishida, Junichi, Konishi, Masaaki, Ebner, Nicole, Springer, Jochen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029061/ https://www.ncbi.nlm.nih.gov/pubmed/27646033 http://dx.doi.org/10.1186/s12967-016-1031-5 |
Ejemplares similares
-
Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment
por: Drescher, Cathleen, et al.
Publicado: (2015) -
Repurposing approved drugs for cancer therapy
por: Schein, Catherine H
Publicado: (2021) -
Repurposing approved drugs on the pathway to novel therapies
por: Schein, Catherine H.
Publicado: (2019) -
The concept that focuses on oral motor and feeding function in cancer patients with muscle wasting: Skeletal muscle mass is associated with severe dysphagia in cancer patients
por: Saitoh, Masakazu, et al.
Publicado: (2016) -
Growth differentiation factor‐15 as a prognostic biomarker in cancer patients
por: Ishida, Junichi, et al.
Publicado: (2016)